Merck & Co., Inc. (NYSE:MRK) Shares Purchased by Builder Investment Group Inc. ADV

Builder Investment Group Inc. ADV increased its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 6.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,226 shares of the company’s stock after purchasing an additional 505 shares during the period. Builder Investment Group Inc. ADV’s holdings in Merck & Co., Inc. were worth $897,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Ruedi Wealth Management Inc. grew its holdings in Merck & Co., Inc. by 180.2% during the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares in the last quarter. AlphaMark Advisors LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth approximately $34,000. Valued Wealth Advisors LLC acquired a new position in Merck & Co., Inc. during the 4th quarter valued at approximately $42,000. TFO Wealth Partners LLC grew its stake in Merck & Co., Inc. by 108.1% during the 3rd quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock worth $48,000 after buying an additional 241 shares during the last quarter. Finally, Ameliora Wealth Management Ltd. acquired a new stake in Merck & Co., Inc. in the third quarter worth $50,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Down 0.5 %

Shares of NYSE MRK traded down $0.71 during trading hours on Tuesday, hitting $130.28. The stock had a trading volume of 2,658,797 shares, compared to its average volume of 8,652,799. The company has a market capitalization of $329.95 billion, a P/E ratio of 935.21, a P/E/G ratio of 0.52 and a beta of 0.38. The firm’s 50-day moving average price is $125.24 and its two-hundred day moving average price is $113.04. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The firm had revenue of $14.63 billion during the quarter, compared to analyst estimates of $14.49 billion. During the same period in the previous year, the company earned $1.62 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Analysts anticipate that Merck & Co., Inc. will post 8.59 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $3.08 annualized dividend and a yield of 2.36%. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the completion of the sale, the insider now directly owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the completion of the sale, the insider now owns 19,569 shares in the company, valued at $2,443,972.41. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares in the company, valued at $2,991,346.35. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on MRK shares. Societe Generale downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target for the company. in a report on Monday, March 11th. Truist Financial reaffirmed a “buy” rating and issued a $142.00 price target (up from $139.00) on shares of Merck & Co., Inc. in a research note on Thursday, March 28th. UBS Group boosted their target price on Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. TD Cowen raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and increased their price target for the company from $125.00 to $135.00 in a research note on Thursday, January 4th. Finally, Wells Fargo & Company boosted their price objective on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.71.

View Our Latest Analysis on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.